NASDAQ:IMTX Immatics Q2 2026 Earnings Report $7.59 -0.85 (-10.07%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$7.59 0.00 (0.00%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immatics EPS ResultsActual EPS-$0.53Consensus EPS -$0.47Beat/MissMissed by -$0.06One Year Ago EPSN/AImmatics Revenue ResultsActual Revenue$10.44 millionExpected Revenue$12.42 millionBeat/MissMissed by -$1.99 millionYoY Revenue GrowthN/AImmatics Announcement DetailsQuarterQ2 2026Date8/18/2026TimeBefore Market OpensConference Call DateTuesday, August 18, 2026Conference Call Time12:30PM ETUpcoming EarningsImmatics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Immatics Earnings HeadlinesImmatics (NASDAQ:IMTX) & Mirum Pharmaceuticals (NASDAQ:MIRM) Critical ContrastSeptember 30 at 5:58 AM | americanbankingnews.comImmatics (NASDAQ:IMTX) Stock Bumped Up to "Hold" by Wall Street ZenSeptember 26, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Immatics and 4 more stocks see action from activist investorsSeptember 4, 2026 | msn.comImmatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer ProgramsAugust 26, 2026 | tipranks.comImmatics N.v Share Price (IMTX.US)August 25, 2026 | lse.co.ukSee More Immatics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email. Email Address About ImmaticsImmatics (NASDAQ:IMTX) (NASDAQ: IMTX) is a biotechnology company focused on developing T cell receptor (TCR)-based therapies for the treatment of cancer. The company identifies cancer targets and designs treatments intended to direct a patient’s immune system toward tumor cells, including solid tumors that may be difficult to address with conventional immunotherapies. Immatics’ technology platforms support several therapeutic approaches, including TCR-engineered T-cell therapies and TCR-based bispecific molecules that can engage both cancer targets and T cells. Its product pipeline has included candidates directed at targets such as PRAME, a tumor-associated antigen expressed in multiple cancers. The company also uses its target-discovery and validation platforms to identify and evaluate cancer antigens for potential drug development. Founded in 2000 and headquartered in Tübingen, Germany, Immatics has expanded its operations internationally, including a presence in the United States. The company develops therapies independently and through collaborations with pharmaceutical and biotechnology partners. Immatics is led by Chief Executive Officer Harpreet Singh, who has been associated with the company since its early development.View Immatics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
